March 13, 2023
3 min watch
Save
VIDEO: ‘Important’ interim results from CaboPoint trial
SAN FRANCISCO — In this video, Moshe Ornstein, MD, discusses interim results from the CaboPoint study presented at the annual ASCO Genitourinary Cancers Symposium.
The prospective phase 2 study investigated the use of cabozantinib (Cabometyx, Exelixis) following checkpoint inhibitor therapy among patients with advanced stage metastatic renal cell carcinoma, according to the abstract.
“Dr. Laurence Albiges presented, what I thought was, a really important study for clinical practice,” Ornstein, genitourinary medical oncologist at Cleveland Clinic Taussig Cancer Institute, said.
Reference:
- Albiges L, et al. Abstract 606. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 16-18, 2022; San Francisco.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Ornstein reports serving as a consultant or in an advisory role for Aveo, Bristol Myers Squibb, Eisai, Exelixis, Merck and Pfizer; serving on speakers bureaus for Bristol Myers Squibb and Merck; receiving institutional research funding from Aravive, Astra-Zeneca, Astellas, Bristol Myers Squibb, Merck, Pfizer and Surface Oncology; and receiving reimbursement for travel and accommodations expenses from Bristol Myers Squibb, Eisai, Exelixis and Pfizer.
Read more about